BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 11134280)

  • 1. Donor- and ligand-dependent differences in C-C chemokine receptor 5 reexpression.
    Sabbe R; Picchio GR; Pastore C; Chaloin O; Hartley O; Offord R; Mosier DE
    J Virol; 2001 Jan; 75(2):661-71. PubMed ID: 11134280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants.
    Mosier DE; Picchio GR; Gulizia RJ; Sabbe R; Poignard P; Picard L; Offord RE; Thompson DA; Wilken J
    J Virol; 1999 May; 73(5):3544-50. PubMed ID: 10196243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.
    Kawamura T; Bruse SE; Abraha A; Sugaya M; Hartley O; Offord RE; Arts EJ; Zimmerman PA; Blauvelt A
    J Virol; 2004 Jul; 78(14):7602-9. PubMed ID: 15220435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES.
    Pastore C; Picchio GR; Galimi F; Fish R; Hartley O; Offord RE; Mosier DE
    Antimicrob Agents Chemother; 2003 Feb; 47(2):509-17. PubMed ID: 12543651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity.
    Mack M; Luckow B; Nelson PJ; Cihak J; Simmons G; Clapham PR; Signoret N; Marsh M; Stangassinger M; Borlat F; Wells TN; Schlöndorff D; Proudfoot AE
    J Exp Med; 1998 Apr; 187(8):1215-24. PubMed ID: 9547333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocytosis and recycling of the HIV coreceptor CCR5.
    Signoret N; Pelchen-Matthews A; Mack M; Proudfoot AE; Marsh M
    J Cell Biol; 2000 Dec; 151(6):1281-94. PubMed ID: 11121442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES.
    Marozsan AJ; Torre VS; Johnson M; Ball SC; Cross JV; Templeton DJ; Quiñones-Mateu ME; Offord RE; Arts EJ
    J Virol; 2001 Sep; 75(18):8624-38. PubMed ID: 11507208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors.
    Hartley O; Gaertner H; Wilken J; Thompson D; Fish R; Ramos A; Pastore C; Dufour B; Cerini F; Melotti A; Heveker N; Picard L; Alizon M; Mosier D; Kent S; Offord R
    Proc Natl Acad Sci U S A; 2004 Nov; 101(47):16460-5. PubMed ID: 15545608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of RANTES- and aminooxypentane-RANTES-triggered desensitization signals reveals differences in recruitment of the G protein-coupled receptor complex.
    Vila-Coro AJ; Mellado M; Martín de Ana A; Martínez-A C; Rodríguez-Frade JM
    J Immunol; 1999 Sep; 163(6):3037-44. PubMed ID: 10477567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
    Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
    J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors.
    Proudfoot AE; Buser R; Borlat F; Alouani S; Soler D; Offord RE; Schröder JM; Power CA; Wells TN
    J Biol Chem; 1999 Nov; 274(45):32478-85. PubMed ID: 10542293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The functional antagonist Met-RANTES: a modified agonist that induces differential CCR5 trafficking.
    Kiss DL; Longden J; Fechner GA; Avery VM
    Cell Mol Biol Lett; 2009; 14(4):537-47. PubMed ID: 19448977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of CC chemokines on CC chemokine receptor 5 (CCR5) phosphorylation and identification of phosphorylation sites on the CCR5 carboxyl terminus.
    Oppermann M; Mack M; Proudfoot AE; Olbrich H
    J Biol Chem; 1999 Mar; 274(13):8875-85. PubMed ID: 10085131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The chemokine CCL5 regulates the in vivo cell surface expression of its receptor, CCR5.
    Lin YL; Mettling C; Portalès P; Rouzier R; Clot J; Reynes J; Corbeau P
    AIDS; 2008 Jan; 22(3):430-2. PubMed ID: 18195571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
    Li H; Liu TJ; Hong ZH
    Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The allergy-associated chemokine receptors CCR3 and CCR5 can be inactivated by the modified chemokine NNY-CCL11.
    Manns J; Rieder S; Escher S; Eilers B; Forssmann WG; Elsner J; Forssmann U
    Allergy; 2007 Jan; 62(1):17-24. PubMed ID: 17156337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of the chemokine receptors CCR1 and CCR5 attenuates chronic rejection.
    Yun JJ; Whiting D; Fischbein MP; Banerji A; Irie Y; Stein D; Fishbein MC; Proudfoot AE; Laks H; Berliner JA; Ardehali A
    Circulation; 2004 Feb; 109(7):932-7. PubMed ID: 14757698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminooxypentane-RANTES, an inhibitor of R5 human immunodeficiency virus type 1, increases the interferon gamma to interleukin 10 ratio without impairing cellular proliferation.
    Rusconi S; La Seta-Catamancio S; Kurtagic S; Galazzi M; Arienti D; Trabattoni D; Wilken J; Thompson DA; Offord RE; Galli M; Clerici M
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):861-7. PubMed ID: 10408722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis.
    Toossi Z; Mayanja-Kizza H; Baseke J; Peters P; Wu M; Abraha A; Aung H; Okwera A; Hirsch C; Arts E
    Clin Exp Immunol; 2005 Nov; 142(2):327-32. PubMed ID: 16232220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.
    Jin J; Colin P; Staropoli I; Lima-Fernandes E; Ferret C; Demir A; Rogée S; Hartley O; Randriamampita C; Scott MG; Marullo S; Sauvonnet N; Arenzana-Seisdedos F; Lagane B; Brelot A
    J Biol Chem; 2014 Jul; 289(27):19042-52. PubMed ID: 24855645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.